Skip to main content

Table 4 Simulation results for the trials which stop at stage 1

From: Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome

  

H R D 1 =0.75

H R D 1 =0.85

 

Design

Under-

%Stop

Estimated H R D for trials stopped at stage 1

 

%Stop

Estimated H R D for trials stopped at stage 1

 

lying

at

At interim point

After follow-up

 

at

At interim point

After follow-up

 

H R D

stage 1

Mean (centilesa)

%Bias

Mean (centilesa)

%Bias

 

stage 1

Mean (centilesa)

%Bias

Mean (centilesa)

%Bias

I outcome: OSb

          

1

1.10

70

1.19(1.01,1.52)

8

1.14(0.95,1.39)

4

 

83

1.13(1.01,1.33)

3

1.12(0.99,1.28)

2

 

1.00

50

1.14(1.00,1.42)

14

1.06(0.89,1.29)

6

 

50

1.08(1.00,1.24)

8

1.05(0.93,1.18)

5

 

0.88

22

1.10(1.00,1.32)

25

0.98(0.81,1.19)

11

 

10

1.04(1.00,1.16)

18

0.97(0.88,1.08)

10

 

0.75

4

1.06(1.00,1.23)

41

0.89(0.75,1.09)

19

 

0.2

1.03(1.00,1.12)

37

0.90(0.82,1.03)

20

2

1.10

95

1.11(0.93,1.36)

1

1.11(0.94,1.32)

1

 

99

1.10(0.98,1.24)

0

1.10(0.99,1.22)

0

 

1.00

80

1.04(0.92,1.25)

4

1.03(0.89,121)

3

 

80

1.02(0.95,1.14)

2

1.02(0.94,1.13)

2

 

0.88

37

0.98(0.91,1.13)

11

0.95(0.84,1.09)

8

 

13

0.98(0.95,1.05)

11

0.95(0.90,1.03)

8

 

0.75

5

0.95(0.91,1.05)

27

0.89(0.80,1.00)

19

 

0

I outcome: PFSc

          

1

1.10

71

1.17(0.81,1.68)

6

1.11(0.92,1.38)

1

 

83

1.13(0.92,1.41)

3

1.11(0.98,1.29)

1

 

1.00

51

1.12(0.79,1.59)

12

1.05(0.87,1.28)

5

 

50

1.07(0.88,1.31)

7

1.04(0.91,1.19)

4

 

0.88

22

1.06(0.77,1.53)

20

0.96(0.80,1.17)

9

 

9

1.01(0.83,1.19)

15

0.95(0.84,1.09)

8

 

0.75

4

1.03(0.72,1.44)

37

0.88(0.71,1.04)

17

 

0

 

 

2

1.10

96

1.11(0.85,1.44)

1

1.09(0.93,1.30)

1

 

99

1.10(0.95,1.28)

0

1.10(0.99,1.24)

0

 

1.00

79

1.04(0.81,1.34)

4

1.02(0.87,1.20)

2

 

79

1.02(0.90,1.16)

2

1.01(0.92,1.13)

1

 

0.88

39

0.97(0.76,1.23)

10

0.94(0.81,1.09)

7

 

13

0.96(0.85,1.07)

9

0.94(0.86,1.04)

7

 

0.75

4

0.92(0.74,1.13)

23

0.87(0.75,0.99)

16

 

0

  1. aThe 2.5th and 97.5th centiles of the estimated OS hazard ratios;
  2. boverall survival;
  3. cprogression-free survival.